Tempus AI, Inc. and Personalis Join Forces to Fight Colorectal Cancer

Tempus AI and Personalis have expanded their partnership to include colorectal cancer. The agreement grants Tempus AI exclusive rights to market its NeXT Personal Minimum Residual Disease test across four oncology types through 2028. Tempus AI has reported a 75% increase in revenue for Q1 2025 and raised its full-year revenue guidance to $1.25 billion. The company offers platforms that combine sequencing diagnostics with algorithmic tools to power data-driven cancer treatment decisions.

Tempus AI and Personalis have significantly expanded their strategic partnership to include colorectal cancer (CRC), marking a pivotal moment in the race for precision oncology diagnostics. The agreement grants Tempus AI exclusive rights to market Personalis' NeXT Personal Minimum Residual Disease (MRD) test across four oncology types, including CRC, through 2028. This expansion underscores the companies' commitment to advancing personalized cancer care and underscores the market's growing demand for early and precise detection.

Tempus AI reported a 75% increase in revenue for Q1 2025, with full-year revenue guidance raised to $1.25 billion. The company's platforms combine sequencing diagnostics with algorithmic tools to power data-driven cancer treatment decisions, positioning it as a leader in the precision oncology space.

The collaboration leverages Personalis' ultra-sensitive MRD assay, capable of detecting CRC recurrence at just 0.01% tumor burden, validated by interim data from the VICTORI study. This precision allows clinicians to identify CRC recurrence up to 16 months earlier than standard imaging methods, potentially transforming CRC treatment and management. By integrating this technology into Tempus' workflow, the collaboration aims to make MRD testing a standard of care, reaching over 50% of U.S. oncologists.

The CRC market is substantial, with over 150,000 new cases annually in the U.S., presenting a $200+ million addressable market. Personalis' Q1 2025 revenue of $20.6 million reflects the partnership's early success, with NeXT Personal® test volumes surging 52% year-over-year. The extended agreement through 2029 and Tempus' exclusive rights until 2028 further solidify their dominance in the MRD market.

Regulatory hurdles and competition from firms like Guardant Health and Foundation Medicine pose risks, but Personalis' proprietary algorithms, Tempus' oncologist network, and real-world data generation through Tempus' clinical studies create a high barrier to entry. Investors should consider the potential for reimbursement decisions for CRC and breast cancer MRD testing, expected by 2026, as a key catalyst for adoption and margin expansion.

Conclusion

This collaboration is more than just a diagnostic tool; it's a cornerstone in reshaping cancer management. By addressing a critical gap in CRC recurrence detection, Tempus AI and Personalis are positioning themselves as leaders in precision oncology. With execution on reimbursement and continued data validation, this partnership could deliver significant returns for investors willing to bet on the future of cancer care.

References:
1. [https://www.ainvest.com/news/personalis-tempus-pioneering-future-colorectal-cancer-care-precision-diagnostics-2507/](https://www.ainvest.com/news/personalis-tempus-pioneering-future-colorectal-cancer-care-precision-diagnostics-2507/)
2. [https://www.biospace.com/press-releases/adagene-announces-regulatory-update-on-clinical-development-plan-for-muzastotug-in-microsatellite-stable-colorectal-cancer-following-productive-type-b-end-of-phase-1-meeting-with-fda](https://www.biospace.com/press-releases/adagene-announces-regulatory-update-on-clinical-development-plan-for-muzastotug-in-microsatellite-stable-colorectal-cancer-following-productive-type-b-end-of-phase-1-meeting-with-fda)